Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Endocrinology and Metabolism|November 1, 1994
Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphyU Plöckinger, M Reichel, U Fett, et al.
European Journal of Endocrinology|June 23, 1999
Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjectsU Plöckinger, J J Holst, D Messerschmidt, et al.
European Journal of Endocrinology|November 20, 1998
Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegalyU Plöckinger, A Perez-Canto, C Emde, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|November 19, 2010
Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LARJ Schopohl, C J Strasburger, D Caird, et al.
European Journal of Endocrinology|August 30, 2008
Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly RegisterS Petersenn, M Buchfelder, M Reincke, et al.
Acta Diabetologica|June 10, 2005
Prevalence of aspirin resistance in patients with type 2 diabetesS Fateh-Moghadam, U Plöckinger, N Cabeza, et al.
European Radiology|January 1, 2005
Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumoursH Amthauer, T Denecke, T Rohlfing, et al.
European Journal of Endocrinology|November 9, 2011
DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumoursU Plöckinger, U Hoffmann, M Geese, et al.
Der Nervenarzt|November 23, 2013
[Diagnosis and therapy of late onset Pompe disease]A Schüller, C Kornblum, M Deschauer, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 4, 2003
Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?H Amthauer, J Ruf, M Böhmig, et al.
Pageof 4